PinCell
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces Appointment of John Mason as Director15.9.2025 13:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 15, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB: CLRMF) is pleased to announce the appointment of John Mason, D.Sc., P.Geo., as Director of the Company effective immediately. John Mason is a professional geoscientist with 49 years of experience in mineral exploration and mining in Northern Ontario. Mr. Mason's work experience includes management positions with the Ontario Ministry of Northern Development and Mines (NDMNRF) and Thunder Bay Community Economic Development Commission, before starting John Mason and Associates. John Mason has worked with all mines and major exploration projects in Northwestern Ontario, specific to supply and service, workforce, energy, and transportation access needs. John has worked with many of the indigenous communities, MNO and municipalities to maximize economic development opportunities related to exploration and mining and balance environmental/ESG require
Honoring Innovation, Excellence, and Leadership at the 2025 APEX/IFSA Awards: APEX Honored Aviation's Industry Trailblazers and Visionaries12.9.2025 08:00:00 CEST | Press release
WASHINGTON, D.C. / ACCESS Newswire / September 12, 2025 / Airlines and suppliers were celebrated for their meaningful advancements in passenger experience at the prestigious APEX/IFSA Awards Ceremony in Long Beach, California. Hosted by the APEX (Airline Passenger Experience Association) and the IFSA (International Flight Services Association) during the APEX/IFSA Global EXPO, the ceremony is regarded as the industry's premier awards event, recognizing innovation, dedication, and leadership that set new standards for excellence across the skies.APEX IFSA "What sets the APEX/IFSA Awards apart comes from how our awards program moves beyond recognition; it actively drives excellence across our entire industry," APEX/IFSA Group CEO Dr. Joe Leader stated. "Unlike other award platforms, these honors reflect both the voices of millions of global passengers and the rigorous assessments of independent experts. This powerful combination establishes the APEX/IFSA Awards as the most trusted and im
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter11.9.2025 21:30:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 11, 2025 / In a new survey, foreign-educated nurses and other healthcare professionals who migrate to work in the United States continue to give high marks to recruitment firms that are certified by the Alliance for Ethical International Recruitment Practices.TruMerit Ethical International Recruitment Report How certification helps safeguard the rights of foreign-educated health professionals. The Alliance, a division of TruMerit (formerly CGFNS International), in 2024 surveyed more than 8,000 foreign-educated health professionals who had used one of its 19 Certified Ethical Recruiters (CERs). Ninety percent of respondents indicated they had an overall positive experience with their recruiter, with 55% reporting it was very positive. As the survey report shows, the high satisfaction rate essentially held steady from 2023 despite persisting delays and increased costs in the U.S. immigration process. In an earlier TruMerit/CGFNS survey of it
Raven Resources Reports Strong First-Year Results Following Grove Electric Acquisition11.9.2025 15:00:00 CEST | Press release
GROVE, OKLAHOMA / ACCESS Newswire / September 11, 2025 / Raven Resources today announced robust first-year financial results following its acquisition of Grove Electric, a leading electrical contracting and services company based in Grove, Oklahoma. For the fiscal year ending August 31, 2025, Grove Electric achieved a 30% increase in revenues compared to the prior year. The September 2024 acquisition was a strategic move to expand Raven Resources' portfolio of service-oriented businesses in fast-growing regional markets. The strong results highlight both the successful integration of Grove Electric and the sustained demand for high-quality electrical contracting services across Northeast Oklahoma. "We are extremely pleased with Grove Electric's first year under Raven Resources," said Paul Scribner, CEO of Raven Resources. "The growth we've seen is a testament to the dedication of Grove Electric's team and the company's reputation for reliable, professional service. This performance rei
Richmond Terrace Capital Secures €900 Million from European Pension Leaders11.9.2025 12:30:00 CEST | Press release
CITY OF LONDON, GB / ACCESS Newswire / September 11, 2025 / Richmond Terrace Capital, a leading London-based investment management company, is pleased to announce that a consortium of leading European pension funds has awarded the firm new discretionary mandates totaling approximately €900 million, with an additional €1.5 billion in commitments scheduled for early 2026. Through these mandates, Richmond Terrace Capital will provide end-to-end portfolio management and strategic investment guidance, designed to deliver consistent value in line with each client's investment objectives. Record Momentum Powered by Strategic Growth This landmark development caps one of Richmond Terrace Capital's strongest years to date, driven by the exceptional performance of its flagship funds and private equity platforms. Investment success has been particularly evident in transformative sectors such as Commercial Space Ventures, Advanced Connectivity Infrastructure, and Artificial Intelligence application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom